التهاب الجلد الغنغريني الذي لم يستجب للعلاج الجهازي

References

DOI: 10.1111/1346-8138.16845

• Presently, experience of the use is richest in anti-TNF preparations.
• As a result, adalimumab was approved first in Japan as a drug for PG covered by health insurance in 2020.
• PGAR100 of target PG ulcers, which was the primary endpoint, was achieved in 12 of 22 patients with active ulcerative PG (p<0.001 at week 26 of administration).